In the News - Q1 Productions

This Week’s Top Headlines

Pfizer Releases Biosimilar Data, Rivals J&J

Posted 2/22/17

At the six-week mark of its fifty-four-week study, Pfizer released data for its biosimilar, Inflectra as a treatment for Crohn’s disease. Previously, Inflectra was approved to treat moderate to severe Crohn’s disease but did not have Crohn’s-specific data. With its new data, the biosimilar may be en route to compete with Johnson & Johnson’s Remicade on a global scale. Though the market success of biosimilar drugs still remains reliant upon physician prescription, Pfizer is confident in moving forward with Crohn’s-focused marketing. Read the full article here.

FDA Approves Biotronik Coronary Stent

Posted 2/22/17

Biotronik has received FDA approval for its first bare-metal stent for coronary arteries. The device is intended for patients with new and recurring blockages in the coronary arteries between 2.25 and 4.0 mm in diameter and lesion lengths up to 31 mm. The PRO-Kinetic Energy Cobalt Chromium Bare-Metal Stent was tested in a global trial of 329 patients. The approval is a milestone for Biotronik as the device will be the first U.S. marketing Biotronik coronary stent. Read the full statement here.

3D Printed Prosthetics Changing Medical Device Landscape

Posted 2/22/17

Due to cost, efficiency, and shorter time frames, many companies have begun printing prosthetics. The devices, used among children and adults alike, have found niche markets in underprivileged countries as the cost of traditional prosthetics rises. Many are claiming that the ability to re-print and re-design the prosthetics in shorter amounts of time enables children to grow with the devices at a less costly rate than being fitted for traditionally engineered limbs, and signals healthcare trends for the future. Read the full article here.

Artificial Intelligence Spotting Skin Cancer

Posted 2/22/17

Researchers from Stanford University have taken AI to the next level, turning computers into dermatologists, or, at least, basic skin cancer detectors. Through an image recognition algorithm, the computer program was able to detect a form of melanoma just as well as a group of dermatologists, suggests one study. The software may be available for public use in the future, as the researchers hope to one day enable smartphones to detect cancerous skin lesions as well. Read the full article here.

Johnson & Johnson Tops Fortune’s 2017 Most Admired Pharma for Fourth Year

Posted 2/22/17

For the fourth year running, Johnson & Johnson has been named as the top most-admired pharmaceutical company of 2017. In a statement about the honor, Johnson & Johnson cited a strong desire to put the consumer first. The top five most-admired pharma companies include Novartis, Roche, Merck, and Amgen. J&J was also included in Fortune’s Top 50 All Stars of 2017. See Fortune’s Most Admired Companies list here.

At Veranex, we can help you with concept through to commercialization by enabling:
• Accelerated speed to market
• Controlled development costs
• Development risk mitigation
• Market viability assessment

At every stage, we navigate our clients to realize efficiencies in cost and time with our integrated and comprehensive solutions.

Visit Sponsor Website

Since TrainingPros was founded in 1997, we have been dedicated to helping our clients find the right consultant for their projects. 25 years later, we are proud to have helped hundreds of clients complete their projects and thousands of consultants find great assignments. We continue to focus on helping our clients and consultants as well as our community as a certified women-owned, award-winning staffing company that works exclusively with Learning & Development professionals to match consultants to client projects.

Visit Sponsor Website

TELCOR is the proven leader of health care software solutions for revenue cycle management (RCM) software and services designed specifically for laboratories. TELCOR RCM, our SaaS solution, and TELCOR Revenue Cycle Services, our billing service, are designed to streamline workflow, improve collections, and provide real-time analytics. Our software and service solutions are designed for the unique challenges and requirements of laboratory specialties and the clients they serve. With full access to data, labs have complete visibility of their data and can track key performance indicators. No other vendor works as hard ensuring you get paid for the work you do.

Visit Sponsor Website

At Tipping Point Media, we pride ourselves on developing innovative, creative, and technically advanced virtual training and digital marketing solutions for the life sciences industry.

We push the limits of what's possible using Augmented and Virtual Reality to create revolutionary experiences proven to increase audience engagement and retention rates.

Our dedicated team of educators, medical experts, certified programmers, and digital renaissance innovators are committed to creating high-quality custom creations that bring your company's vision to life.

Visit Sponsor Website

VantagePoint Performance trains Salespeople to be more fluent and comfortable across different situations needing different sales approaches, and we train Sales Managers to be better coaches and team leaders, with more focus and less stress.

We’re different from the average sales training company because:

We don’t believe that one approach, one system, or one methodology is absolutely superior. All have something to offer, and the “best approach” or “best system” depends on the sales situation. This is what our applied, academic research tells us.
Our use of data science, specifically Machine Learning, helps us learn about our clients more meaningfully. We provide insights from each client’s data to help them understand what drives the success of their top-performing Salespeople and Sales Managers.
We are constantly feeding what we learn back into our training products, and we invest a bigger slice of our total energy into this innovation than the average sales training company. Our clients can access always-refreshed intellectual property and content through our training subscriptions.

Visit Sponsor Website

Policy Reporter, acquired by TrialCard in 2019, provides innovative healthcare software solutions to track payer policies in near real-time and enhances market access for the therapies patients need most. The company’s patented software-driven solutions include a suite of billing and reimbursement tools for providers and laboratories, market intelligence tools for payers, and a suite of market access solutions for life science companies. Its clients include some of the world’s largest pharmaceutical and healthcare companies.

Visit Sponsor Website